Pulmatrix

PULMPhase 2

Pulmatrix is dedicated to improving the lives of patients with severe respiratory and other diseases through its innovative dry powder inhalation platform, iSPERSE™. This technology allows for high drug loads, efficient lung delivery, and stable formulations of challenging compounds. The company's lead program, PUR3100, is an inhaled dihydroergotamine (DHE) in development for acute migraine, representing a novel, non-systemic treatment approach. Pulmatrix's strategy includes advancing its proprietary pipeline and pursuing strategic collaborations to leverage its platform.

Market Cap

$9.1M

Employees

11-50

Focus

Biotech

PULM · Stock Price

USD 2.494.19 (-62.72%)

Historical price data

AI Company Overview

Technology Platform

iSPERSE™ is an engineered dry powder inhalation platform designed for high drug loading, efficient lung delivery, and stable formulation of small molecules and biologics.

Pipeline Snapshot

13 drugs in pipeline

Drug	Indication	Stage
Itraconazole Powder + Placebo	ABPA	Phase 2
RUT058-60 + Sterile saline for irrigation	Postoperative Wound Infection-deep	Phase 1/2
PUR118	Chronic Obstructive Pulmonary Disease (COPD)	Phase 1
Itraconazole Powder + Itraconazole 200 mg	Asthma	Phase 1
PUR003 + Placebo	Healthy	Phase 1

Opportunities

Positive Phase 2 data for PUR3100 could unlock significant value in the large acute migraine market and validate the iSPERSE™ platform for systemic delivery.

The platform's versatility presents opportunities for new partnerships to reformulate other high-value drugs for inhaled administration in both pulmonary and systemic diseases.

Risk Factors

The company faces high clinical risk with its lead asset, financial risk due to its pre-revenue status and need for additional capital, and intense competition in its target therapeutic areas.

Regulatory hurdles for novel inhaled drug-device combinations also present a significant challenge.

Competitive Landscape

Pulmatrix competes with large pharma in respiratory (GSK, AZ) and neurology (AbbVie, Pfizer), and biotechs with alternative migraine therapies. Its differentiation is the iSPERSE™ platform's ability to deliver high drug doses via inhalation, offering a potential best-in-class profile for rapid, non-oral systemic drugs like DHE for migraine.